Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectinAnthony W Tolcher, Christopher J Sweeney, Kyri Papadopoulos, et al.
Autophagy|July 4, 2014
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumorsDevalingam Mahalingam, Monica Mita, John Sarantopoulos, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
British Journal of Cancer|June 21, 2019
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasChia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumorsAlain C Mita, Chris H Takimoto, Monica Mita, et al.
Journal of Hematology & Oncology|August 19, 2021
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancerApostolia-Maria Tsimberidou, Jamie V Shaw, Dejan Juric, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Targeted Oncology|August 10, 2020
Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in CancerEric Vail, Jianbo Song, Jing Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Pageof 6